Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $54.45 million. The enterprise value is $124.54 million.
Important Dates
The next estimated earnings date is Friday, December 5, 2025, after market close.
| Earnings Date | Dec 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 26.69 million shares outstanding. The number of shares has increased by 12.89% in one year.
| Current Share Class | 26.69M |
| Shares Outstanding | 26.69M |
| Shares Change (YoY) | +12.89% |
| Shares Change (QoQ) | +2.08% |
| Owned by Insiders (%) | 12.14% |
| Owned by Institutions (%) | 13.30% |
| Float | 14.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.02 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
| Current Ratio | 0.25 |
| Quick Ratio | 0.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.96 |
Financial Efficiency
Return on equity (ROE) is -6,367.24% and return on invested capital (ROIC) is -42.33%.
| Return on Equity (ROE) | -6,367.24% |
| Return on Assets (ROA) | -23.14% |
| Return on Invested Capital (ROIC) | -42.33% |
| Return on Capital Employed (ROCE) | -92.74% |
| Revenue Per Employee | $362,520 |
| Profits Per Employee | -$598,935 |
| Employee Count | 123 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 5.47 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.84% in the last 52 weeks. The beta is 0.76, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -9.84% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 45.02 |
| Average Volume (20 Days) | 171,279 |
Short Selling Information
The latest short interest is 640,091, so 2.40% of the outstanding shares have been sold short.
| Short Interest | 640,091 |
| Short Previous Month | 1.40M |
| Short % of Shares Out | 2.40% |
| Short % of Float | 4.42% |
| Short Ratio (days to cover) | 3.10 |
Income Statement
In the last 12 months, Celularity had revenue of $44.59 million and -$73.67 million in losses. Loss per share was -$3.21.
| Revenue | 44.59M |
| Gross Profit | 24.57M |
| Operating Income | -47.35M |
| Pretax Income | -73.67M |
| Net Income | -73.67M |
| EBITDA | -39.91M |
| EBIT | -47.35M |
| Loss Per Share | -$3.21 |
Full Income StatementBalance Sheet
The company has $863,000 in cash and $70.15 million in debt, giving a net cash position of -$69.29 million or -$2.60 per share.
| Cash & Cash Equivalents | 863,000 |
| Total Debt | 70.15M |
| Net Cash | -69.29M |
| Net Cash Per Share | -$2.60 |
| Equity (Book Value) | -25.50M |
| Book Value Per Share | -1.04 |
| Working Capital | -51.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.54 million and capital expenditures -$91,000, giving a free cash flow of -$2.63 million.
| Operating Cash Flow | -2.54M |
| Capital Expenditures | -91,000 |
| Free Cash Flow | -2.63M |
| FCF Per Share | -$0.10 |
Full Cash Flow StatementMargins
Gross margin is 55.10%, with operating and profit margins of -106.19% and -165.21%.
| Gross Margin | 55.10% |
| Operating Margin | -106.19% |
| Pretax Margin | -165.21% |
| Profit Margin | -165.21% |
| EBITDA Margin | -89.51% |
| EBIT Margin | -106.19% |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.89% |
| Shareholder Yield | -12.89% |
| Earnings Yield | -133.33% |
| FCF Yield | -4.77% |
Analyst Forecast
The average price target for Celularity is $6.00, which is 194.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 194.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -12.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.23 |
| Piotroski F-Score | 2 |
